Synexus recently randomised more than 1300 patients in a vaccine study at five sites across Europe over a three week period, as part of a global programme.
Dr. Ravi Pawa has been appointed Medical Advisor at Synexus (from 22nd September), joining Dr. John Robinson, Senior Medical Advisor in the newly created Global Medical Affairs Department. Synexus
which is based in Manchester, England is a world leader in the recruitment and running of clinical trials at its own dedicated research centres.
Synexus, a world leader in the recruitment and running of clinical trials, increased its turnover by more than fifty percent in the first half of the year to more than $30million.
Synexus can now dramatically reduce the time taken for running Phase II studies. Synexus, which is the world leader in recruiting and running late stage clinical trials, is able to do this by running the whole of a Phase II trial at its hubsites across the world.
Synexus has appointed Dr. Sándor Kis country manager of Hungary.
Synexus - the world's largest multi-national company specialising in the recruitment and running of late-stage clinical trials - is extending the scope of its studies to include Phase IV trials following the recent running of successful Phase IV studies for major pharmaceutical companies.
Synexus has significantly increased its capacity to recruit and run global osteoporosis trials by increasing the number of DEXA scanners at its hub sites by a third. According to the American College of Radiology the DEXA scan is the most reliable way of identifying osteoporosis and is the best test for measuring bone mineral density
1.
Synexus has achieved a new record for an organisation, which recruits and runs clinical trials, with more than 10,000 patients currently enrolled in late stage clinical trials at 14 hub sites in six countries.
Using just eight of its 14 hub sites
Synexus recruited and randomised more than 2740 of the 15,000 patients involved in AstraZeneca's Crestor Jupiter study into cardiovascular disease.
Follow Synexus on Twitter
Back to top ^
